Paul Glavine Purchases 100,000 Shares of Cybin (NASDAQ:HELP) Stock

Cybin Inc. (NASDAQ:HELP) insider Paul Glavine bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were purchased at an average price of $11.78 per share, with a total value of $1,178,000.00. Following the transaction, the insider directly owned 4,171,252 shares in the company, valued at $49,137,348.56. This represents a 2.46% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Paul Glavine also recently made the following trade(s):

• On Tuesday, September 8th, Paul Glavine purchased 100,000 shares of Cybin stock. The stock was purchased at an average price of $12.47 per share, for a total transaction of $1,247,000.00.
• On Monday, August 31st, Paul Glavine acquired 90,000 shares of Cybin stock. The shares were purchased at an average cost of $11.59 per share, for a total transaction of $1,043,100.00.

Cybin Trading Up 1.0%

NASDAQ HELP opened at $12.97 on Friday. The firm has a market cap of $980.66 million, a price-to-earnings ratio of -4.29 and a beta of 0.63. The company has a 50 day moving average of $9.97 and a 200-day moving average of $6.89. Cybin Inc. has a 1-year low of $3.76 and a 1-year high of $14.35.

Cybin (NASDAQ:HELP) last announced its earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.11). On average, analysts forecast that Cybin Inc. will post -2.95 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HELP. TD Cowen raised their target price on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Wells Fargo & Company began coverage on shares of Cybin in a report on Monday, July 27th. They set an “overweight” rating and a $16.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Cybin from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, Cybin currently has a consensus rating of “Buy” and a consensus target price of $48.60.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its position in Cybin by 46.7% in the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after buying an additional 2,400 shares during the last quarter. AXQ Capital LP bought a new stake in shares of Cybin during the second quarter worth $75,000. Bank of America Corp DE lifted its stake in shares of Cybin by 66.8% during the second quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock valued at $247,000 after acquiring an additional 11,790 shares during the period. Pale Fire Capital SE acquired a new position in shares of Cybin during the second quarter valued at $1,015,000. Finally, Millennium Management LLC boosted its holdings in Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock valued at $8,414,000 after acquiring an additional 959,448 shares during the last quarter. 17.94% of the stock is currently owned by institutional investors.

More Cybin News

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Insider Paul Glavine bought 100,000 shares for approximately $1.25 million on September 8, increasing his direct ownership by 2.40%. Insider Eric H. L. So also purchased 100,000 shares for about $1.24 million, lifting his stake by 2.29%. These transactions follow additional purchases by both insiders in late August and early September, representing a notable pattern of open-market buying and likely supporting investor confidence. Eric So SEC filing Paul Glavine SEC filing
• Positive Sentiment: Cybin’s commercial operations are scheduled to receive investor exposure at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. CEO Michael Halstead is expected to participate in a fireside chat, potentially providing updates on the company’s psychedelic-based mental-health drug pipeline. Morgan Stanley conference announcement
• Neutral Sentiment: Reported short interest was zero shares with a zero-day days-to-cover ratio. However, the filing also showed an invalid “NaN” percentage change, making the data unreliable as an indicator of short-selling pressure.
• Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share was worse than the expected $0.80 loss, and analysts project a full-year loss of approximately $2.95 per share. With no new trial result or regulatory approval reported, valuation and future financing needs remain important risks after the stock’s sharp advance.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.